Stockscreener 앱 받기
8.16
2.28%
-0.19
시간 외 거래:
8.00
-0.16
-1.96%
전일 마감가:
$8.35
열려 있는:
$8.2
하루 거래량:
957.07K
Relative Volume:
0.67
시가총액:
$543.46M
수익:
$2.81M
순이익/손실:
$-97.34M
주가수익비율:
-5.1646
EPS:
-1.58
순현금흐름:
$-91.47M
1주 성능:
-6.53%
1개월 성능:
-14.55%
6개월 성능:
+6.53%
1년 성능:
+151.08%
1일 변동 폭
$7.93
$8.24
1주일 범위
$7.52
$8.835
52주 변동 폭
$2.315
$15.74
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
명칭
Fulcrum Therapeutics Inc
전화
617-651-8851
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
8.16 | 556.11M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-12 | 개시 | JP Morgan | Overweight |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-07-29 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-09-12 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-09-09 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-05-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 개시 | RBC Capital Mkts | Outperform |
| 2023-09-25 | 개시 | Goldman | Neutral |
| 2023-08-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | 업그레이드 | Stifel | Hold → Buy |
| 2023-05-04 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-03-10 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-02-28 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-11-15 | 개시 | Goldman | Buy |
| 2022-03-08 | 개시 | Oppenheimer | Outperform |
| 2022-03-03 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-08-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-22 | 개시 | Credit Suisse | Outperform |
| 2021-03-02 | 개시 | Stifel | Buy |
| 2020-10-16 | 개시 | Piper Sandler | Overweight |
| 2020-08-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-08-12 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-12 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2019-10-03 | 개시 | H.C. Wainwright | Buy |
| 2019-08-12 | 개시 | BofA/Merrill | Buy |
모두보기
Fulcrum Therapeutics Inc 주식(FULC)의 최신 뉴스
Hedge Fund Moves: Is Fulcrum Therapeutics Inc part of any ETFJuly 2025 Reactions & Daily Profit Maximizing Tips - baoquankhu1.vn
FULC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference - Bitget
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 7.5%Here's Why - MarketBeat
FULC Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Winners Losers: Can Fulcrum Therapeutics Inc keep up with sector leadersBond Market & Stepwise Swing Trade Plans - baoquankhu1.vn
Fulcrum: Strong HbF Signal, Narrow TAM, Same 'Hold' Conclusion (NASDAQ:FULC) - Seeking Alpha
Fulcrum Therapeutics, Inc. (FULC): Analyst Ratings Suggest 111% Upside Potential – Is It Time to Buy? - DirectorsTalk Interviews
HC Wainwright Has Optimistic Outlook of FULC Q1 Earnings - MarketBeat
FY2030 Earnings Forecast for FULC Issued By HC Wainwright - Defense World
Fulcrum Therapeutics move lower ‘overdone,’ says Stifel - Yahoo Finance
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2025 Earnings Call Transcript - Insider Monkey
H.C. Wainwright Maintains Buy on FULC Fulcrum Therapeutics, Inc. Feb 24, 2026 - Meyka
Fulcrum Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Fulcrum Therapeutics stock falls as sickle cell trial misses target - Investing.com Australia
Fulcrum Therapeutics stock falls as sickle cell trial misses target By Investing.com - Investing.com Canada
Leerink reiterates Fulcrum Therapeutics stock rating on SCD data By Investing.com - Investing.com Canada
Fulcrum Therapeutics shares fall on profit-taking, Oppenheimer says By Investing.com - Investing.com Canada
BofA reiterates Fulcrum Therapeutics stock Underperform rating at $7 By Investing.com - Investing.com Canada
Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap DownWhat's Next? - MarketBeat
Fulcrum Therapeutics Shares Surge on Promising Clinical Trial Data and Strong Financial Runway - NewsCase
Positive Developments in Fulcrum Therapeutics (FULC) Boost Inves - GuruFocus
Fulcrum Therapeutics Q4 Earnings Call Highlights - MarketBeat
Fulcrum Therapeutics (FULC) Shares Experience Unexpected Decline - GuruFocus
Fulcrum Therapeutics (FULC) Surpasses Expectations with Phase Ib Study Results - GuruFocus
FULC: Pociredir at 20 mg achieved strong HbF induction and clinical benefit in severe sickle cell disease - TradingView
What's Going On With Fulcrum Therapeutics Stock Tuesday? - Benzinga
Fulcrum Therapeutics Says Phase 1b Pociredir Trial Demonstrates Improvement in Sickle Cell Disease Therapy - marketscreener.com
Earnings call transcript: Fulcrum Therapeutics Q4 2025 reports progress in sickle cell treatment - Investing.com
Fulcrum Therapeutics (NASDAQ:FULC) Releases Quarterly Earnings Results, Meets Expectations - MarketBeat
Fulcrum Therapeutics (FULC) Reports Promising PIONEER Trial Resu - GuruFocus
Fulcrum Therapeutics stock tumbles despite trial results By Investing.com - Investing.com Canada
Biopharmaceutical company Fulcrum Therapeutics recently disclosed that by the end of 2025, its total holdings of cash, cash equivalents, and marketable securities will reach $352.3 million. - Bitget
Fulcrum Therapeutics stock tumbles despite trial results - Investing.com Australia
FULCRUM THERAPEUTICS ($FULC) Releases Q4 2025 Earnings - Quiver Quantitative
Fulcrum Therapeutics, Inc. SEC 10-K Report - TradingView
Fulcrum Therapeutics announces positive results from 20 mg dose cohort of phase 1b pioneer trial of Pociredir - marketscreener.com
Fulcrum Therapeutics (NASDAQ: FULC) posts wider 2025 loss and boosts cash runway - Stock Titan
Fulcrum Therapeutics Announces Recent Business Highlights - GlobeNewswire
Experimental sickle cell pill left most patients crisis-free for 12 weeks - Stock Titan
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025 - Bitget
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - Bitget
Aberdeen Group plc Acquires 79,265 Shares of Fulcrum Therapeutics, Inc. $FULC - Defense World
Will Fulcrum Therapeutics Inc. stock benefit from infrastructure spending2025 Pullback Review & Low Drawdown Momentum Trade Ideas - mfd.ru
Fulcrum Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
Why Fulcrum Therapeutics Inc. stock attracts high net worth investorsEarnings Recap Report & Reliable Volume Spike Alerts - mfd.ru
Fulcrum Therapeutics (NASDAQ:FULC) Trading 6.5% HigherWhat's Next? - MarketBeat
Fulcrum Therapeutics, Inc. (FULC) Stock Analysis: Unpacking The 74.59% Potential Upside - DirectorsTalk Interviews
Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - The Manila Times
Fulcrum Therapeutics (FULC) to Release Quarterly Earnings on Tuesday - MarketBeat
Is Fulcrum Therapeutics Inc. stock a contrarian buyPortfolio Risk Report & Fast Gain Stock Tips - mfd.ru
Fulcrum Therapeutics Inc (FULC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.69%
0.68%
자본화:
|
볼륨(24시간):